Health
Jaguar Health Extends Collaboration for Possible Tropical Disease Priority Review Voucher and Cholera Indication for NP-300
Priority Review Vouchers (PRVs) are transferable and, in past transactions by other companies, have sold for prices up to $350 million 1.3 to 4 million cholera cases and 21,000 to 143,000 cholera-related deaths occur each year worldwide SAN FRANCISCO, ...
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Priority Review Vouchers (PRVs) are transferable and, in past transactions by other companies, have sold for prices up to $350 million","length":134,"tagName":"p"},{"type":"text","content":"1.3 to 4 million cholera cases and 21,000 to 143,000 cholera-related deaths occur each year worldwide","length":101,"tagName":"p"},{"type":"text","content":"SAN FRANCISCO, CA / ACCESS Newswire / February 18, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") and Jaguar family company Napo Pharmaceuticals ("Napo") today announced that, on January 29, 2025, they extended their collaboration with Streeterville related to Napo's plans to develop its NP-300 drug product candidate for the symptomatic relief of diarrhea and dehydration in cholera patients and pursue a possible Tropical Disease Priority Review Voucher ("TDPRV") from the U.S. Food and Drug Administration ("FDA") for this indication.","length":614,"tagName":"p"},{"type":"text","content":"With the sunset of the FDA's Rare Pediatric Disease PRV program in December 2024, and the sunset of the FDA's Medical Countermeasures PRV Program in October 2023, the TDPRV Program is currently the FDA's only active PRV program - so there will possibly be fewer PRVs available for purchase, which could increase the value of TDPRVs, spurring increased interest and investment in tropical diseases.","length":409,"tagName":"p"},{"type":"text","content":""We at Jaguar and Napo find it very rewarding to work in the pharmaceutical industry and be in a position to possibly help address such an important global health need and meet stakeholder expectations," stated Lisa Conte, Jaguar's founder, president, and CEO. "We are thankful to both the FDA for creating the TDPRV Program to drive development of drugs to benefit patients suffering from serious but often neglected tropical diseases, and to Streeterville for their commitment to this unmet need in cholera patients. Streeterville has extended the due date until January 2026 for the funding they provided Napo for this clinical development program."","length":676,"tagName":"p"},{"type":"text","content":"PRV programs incentivize the development of therapies for underfunded diseases. A PRV entitles the bearer to regulatory review by the FDA in approximately s...